| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445222 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
Heterogeneous FDG-PET responses are common in metastatic melanoma treated with dabrafenib, and heterogeneity is associated with a shorter TTP. FDG-PET heterogeneity may predict molecular heterogeneity, and FDG-PET directed biopsies may facilitate investigation into mechanisms of resistance to signal pathway inhibitors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Matteo S. Carlino, Catherine A.B. Saunders, Lauren E. Haydu, Alexander M. Menzies, C. Jr., Peter F. Lebowitz, Richard F. Kefford, Georgina V. Long,